CureVac

DGAP-News: CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

Retrieved on: 
Wednesday, November 10, 2021
Safety, SITC, Neck, Squamous cell carcinoma, European Society of Gene and Cell Therapy, RNA transfection, Neoplasm, Infection, Melanoma, RNA, Immune system, Technology, Degenerative disease, Society, CureVac, COVID-19, ESMO, PD-1, Adenoid cystic carcinoma, Society for Immunotherapy of Cancer, Protein, Conference, European Society for Medical Oncology, Immunotherapy, Oncology, B cell, Skin, Nasdaq, Patient, CVAC, GSK, Head, Cell, Vaccine, Pharmaceutical industry, CV8102 and the Phase 1 Clinical Trial, CureVac, CV8102 AND THE PHASE 1 CLINICAL TRIAL, CUREVAC

Extensive analysis of immune cell activation shows efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma signaling pathways.

Key Points: 
  • Extensive analysis of immune cell activation shows efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma signaling pathways.
  • Serial tumor biopsies from individual patients demonstrated increased infiltration of tumor-fighting T cells in the microenvironment of injected as well as non-injected tumors.
  • The data are being presented at the Society for Immunotherapy of Cancer (SITC) Conference, held in Washington, D.C., and virtually from November 10-14, 2021.
  • "The preliminary data from the Phase 1 dose escalation part of this study allow a much deeper understanding of the promising biologic effects of CV8102 observed in several patients," said Dr. Klaus Edvardsen, Chief Development Officer at CureVac.

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

Retrieved on: 
Monday, October 25, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, RNA transfection, Duke–NUS Medical School, Takeda Pharmaceutical Company, Cystic Fibrosis Foundation, Hepatitis B virus, Glycogen storage disease type III, LinkedIn, Vaccine, III, Cystic fibrosis, ARCT, Messenger RNA, Twitter, Janssen Pharmaceuticals, RNA, Severe acute respiratory syndrome coronavirus 2, Johnson & Johnson, Patent, OTC, COVID-19, Diversified Specialty Institute Holdings, Inc., Nasdaq, Fatty liver disease, NASH, MicroRNA, Therapy, CureVac, Gene editing, DNA, Baking

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • In addition, please connect with us on Twitter and LinkedIn .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005719/en/

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, October 21, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Safety, RNA transfection, Duke–NUS Medical School, Takeda Pharmaceutical Company, Cystic Fibrosis Foundation, Director, LinkedIn, Vaccine, Cystic fibrosis, ARCT, Hepatitis B virus, Messenger RNA, Twitter, Janssen Pharmaceuticals, Private Securities Litigation Reform Act, RNA, SEC, Infection, Severe acute respiratory syndrome coronavirus 2, Annual report, Glycogen storage disease, Johnson & Johnson, Company, Patent, Risk, Financial compensation, Intention, OTC, COVID-19, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Nasdaq, Fatty liver disease, NASH, MicroRNA, Employment, Therapy, CureVac, Liver, Gene editing, DNA

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $46.98 per share, the closing price of the Companys common stock as reported by Nasdaq on October 15, 2021.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

DGAP-News: dievini explains reasons for changes in shareholdings in CureVac due to legal restructuring and obligations under a share program

Retrieved on: 
Monday, October 18, 2021
SAP, Kommanditgesellschaft, Gesellschaft mit beschränkter Haftung, Cancer, Therapy, HOB GmbH & Co KG, Schedule, Vaccine, Investment, Cyprus Securities and Exchange Commission, Biotechnology, Spanish mythology, Sale, Person, Neurodegeneration, CureVac, Security (finance), Pharmaceutical industry

DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG

Key Points: 
  • DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG
    The issuer is solely responsible for the content of this announcement.
  • Due to these changes and reduction in the beneficial ownership, the amendment was required by law without undue delay.
  • The amendment does not reflect any intent of dievini to exit its investment in CureVac nor does it change dievini's confidence in and commitment to CureVac.
  • dievini Hopp BioTech holding GmbH & Co. KG is a holding company of SAP co-founder Dietmar Hopp with an investment focus on innovative biotechnology companies.

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Retrieved on: 
Tuesday, October 12, 2021
Research, Infectious Diseases, Public Relations, Investor Relations, Communications, Health, Pharmaceutical, General Health, Other Science, Science, Hepatitis B virus, Private Securities Litigation Reform Act, Twitter, Injection, Patent, Therapy, Cystic Fibrosis Foundation, Takeda Pharmaceutical Company, Emergency Use Authorization, OTC, Fatty liver disease, Cystic fibrosis, Liver, Intention, COVID-19, Janssen Pharmaceuticals, Program, Glycogen storage disease, EUA, LinkedIn, Safety, ARCT, Annual report, SEC, Review, Gene editing, Vaccination, Johnson & Johnson, Arcturus Therapeutics, Infection, MicroRNA, Vaccine, RNA, Diversified Specialty Institute Holdings, Inc., RNA transfection, Duke–NUS Medical School, Severe acute respiratory syndrome coronavirus 2, CEO, DNA, Messenger RNA, CureVac, Risk, Nasdaq, COVID-19 vaccine, NASH, Pharmaceutical industry

Arcturus Therapeutics and Vinbiocare remain on track to potentially file an Emergency Use Authorization (EUA) for ARCT-154 in Vietnam in December 2021.

Key Points: 
  • Arcturus Therapeutics and Vinbiocare remain on track to potentially file an Emergency Use Authorization (EUA) for ARCT-154 in Vietnam in December 2021.
  • The Phase 1 part of the trial has completed the priming vaccination series with two administrations in 100 participants (75 in ARCT-154 arm).
  • The Phase 2 and Phase 3a parts of the trial are ongoing with 300 (225 in ARCT-154 arm) and 600 (450 in ARCT-154 arm) participants, respectively.
  • The approval to proceed with the Phase 3b portion of the study follows the review of safety data from the initial 1,000 participants included in the Phase 1/2/3a cohorts of the ARCT-154 study.

DGAP-News: CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

Retrieved on: 
Tuesday, October 12, 2021
Virtual press conference, CVAC, Public health, Royal commission, CET, CureVac COVID-19 vaccine, COVID-19, European Commission, Protein, GSK, Webcast, European Medicines Agency, Vaccine, EST, Communication, EMA, Infection, RNA, RNA transfection, Degenerative disease, Partnership, CureVac, Technology, Nasdaq, Investor relations, Pharmaceutical industry

Published pre-clinical results have shown the strong potential of the initial second-generation mRNA COVID-19 vaccine candidate, CV2CoV, compared to CureVac's first generation mRNA, CVnCoV.

Key Points: 
  • Published pre-clinical results have shown the strong potential of the initial second-generation mRNA COVID-19 vaccine candidate, CV2CoV, compared to CureVac's first generation mRNA, CVnCoV.
  • In parallel to the work on the second-generation mRNA vaccine technology, GSK and CureVac will accelerate efforts to progress the development of modified mRNA vaccine constructs.
  • To complement the development of this second generation non-modified mRNA technology, we have also initiated the development of modified mRNA technologies as part of our collaboration."
  • This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies.

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

Retrieved on: 
Wednesday, September 22, 2021
Health, Infectious Diseases, Genetics, Other Science, Research, Science, Pharmaceutical, Hepatitis B virus, Patent, Gene editing, RNA transfection, Janssen Pharmaceuticals, Vaccine, OTC, RNA, Risk, Annual report, Therapy, ARCT, Takeda Pharmaceutical Company, Private Securities Litigation Reform Act, DNA, Intention, CureVac, Glycogen storage disease, Population, SEC, LinkedIn, Infection, NASH, COVID-19 vaccine, Twitter, Public health, CEO, Company, Messenger RNA, Liver, COVID-19, Johnson & Johnson, MicroRNA, Severe acute respiratory syndrome coronavirus 2, Cystic fibrosis, Duke–NUS Medical School, Safety, Fatty liver disease, Kirkbi AG v Ritvik Holdings Inc, Cystic Fibrosis Foundation, Nasdaq, Vingroup, Pharmaceutical industry

It was an honor to meet with President Nguyen Xuan Phuc and the delegation to discuss Vietnams progressive public health strategy.

Key Points: 
  • It was an honor to meet with President Nguyen Xuan Phuc and the delegation to discuss Vietnams progressive public health strategy.
  • Vietnam should be acknowledged for its thoughtful planning and aggressive actions to combat this pandemic, including its proactive approach to secure early access to vaccines targeting SARS-CoV-2 variants of concern.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (231 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Retrieved on: 
Wednesday, September 22, 2021
Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Hepatitis B virus, Patent, Gene editing, RNA transfection, Janssen Pharmaceuticals, Vaccine, OTC, RNA, Risk, Annual report, Therapy, ARCT, Takeda Pharmaceutical Company, Private Securities Litigation Reform Act, DNA, Intention, CureVac, Glycogen storage disease, SEC, LinkedIn, Infection, NASH, COVID-19 vaccine, Twitter, CEO, Company, Messenger RNA, Liver, COVID-19, Johnson & Johnson, MicroRNA, Severe acute respiratory syndrome coronavirus 2, Injection, Cystic fibrosis, Duke–NUS Medical School, Safety, Fatty liver disease, Diversified Specialty Institute Holdings, Inc., Cystic Fibrosis Foundation, Nasdaq, Pharmaceutical industry

The Vietnam Ministry of Health has reviewed the safety data following both injections in the Phase 1 part of the study and has given permission to proceed with enrollment of Phase 2 and Phase 3a.

Key Points: 
  • The Vietnam Ministry of Health has reviewed the safety data following both injections in the Phase 1 part of the study and has given permission to proceed with enrollment of Phase 2 and Phase 3a.
  • Emergency Use Authorization filing in Vietnam could be as soon as December 2021.
  • The tolerability profile of ARCT-154 in the Phase 1 study was favorable.
  • We are very pleased, together with our partner Vinbiocare, to have rapidly completed enrollment and dosing of the ARCT-154 Phase 1 study, and to receive approval to proceed into Phase 2/3a.

Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots

Retrieved on: 
Friday, September 17, 2021
Cancer, University, BNTX, Antigen, AZN, Technology, AstraZeneca, CAGR, Quality control, Immune system, Protein, Patient, MAGE, Pembrolizumab, Patent, BioNTech, COVID-19, GMP, GLP, MRNA, Safety, Moderna, Infection, News, CSE, Vaccine, CureVac, NASDAQ, CVAC, Merck, Boehringer Ingelheim, Large-cell lung carcinoma, COTA, NSCLC, Partnership, CMO, RNA transfection, PCV, Frustration, Eye, Time, SE, Research, Pharmaceutical industry

As well, as BioElpida is advancing preparations for GMP manufacturing of BVX-0918A, the preparation of the new manufacturing facility is ongoing and on schedule.

Key Points: 
  • As well, as BioElpida is advancing preparations for GMP manufacturing of BVX-0918A, the preparation of the new manufacturing facility is ongoing and on schedule.
  • "This major step is essentially a 'dry-run' for manufacturing the vaccine and preparation for GMP production,"said BioElpida President Gilles Devilliers.
  • Researchers behind the AstraZeneca PLC (AZN) candidate have designed a two-dose cancer vaccine using the same viral vector technology used in its Covid-19 treatment.
  • According to analysts , the mRNA cancer vaccine market is expected to boom to $127 billion at a CAGR of +28% between 2021-2028.

Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots

Retrieved on: 
Friday, September 17, 2021
Cancer, University, BNTX, Antigen, AZN, Technology, AstraZeneca, CAGR, Quality control, Immune system, Protein, Patient, MAGE, Pembrolizumab, Patent, BioNTech, COVID-19, GMP, GLP, MRNA, Safety, Moderna, Infection, News, CSE, Vaccine, CureVac, NASDAQ, CVAC, Merck, Boehringer Ingelheim, Large-cell lung carcinoma, COTA, NSCLC, Partnership, CMO, RNA transfection, PCV, Frustration, Eye, Time, SE, Research, Pharmaceutical industry

VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- USA News Group  -  Using the same technology as their Covid-19 shot, scientists behind the University of Oxford and AstraZeneca PLC (NASDAQ:AZN) are getting closer to developing a therapeutic cancer vaccine, based on promising animal studies results. Based on the rapidly accelerating development of Covid-19 tech, expectations are rising in the field of oncology to keep pace, with a COTA survey reporting two-thirds (66%) of cancer patients and their close family members reporting disappointment or frustration with the progress of investigational cancer treatments. Thankfully, AstraZeneca isn't the only group in this fight, with several promising developments coming from other biotech firms, such as BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF), BioNTech SE (NASDAQ:BNTX), CureVac N.V. (NASDAQ:CVAC), and Moderna, Inc. (NASDAQ:MRNA).

Key Points: 
  • As well, as BioElpida is advancing preparations for GMP manufacturing of BVX-0918A, the preparation of the new manufacturing facility is ongoing and on schedule.
  • "This major step is essentially a 'dry-run' for manufacturing the vaccine and preparation for GMP production,"said BioElpida President Gilles Devilliers.
  • Researchers behind the AstraZeneca PLC (AZN) candidate have designed a two-dose cancer vaccine using the same viral vector technology used in its Covid-19 treatment.
  • According to analysts , the mRNA cancer vaccine market is expected to boom to $127 billion at a CAGR of +28% between 2021-2028.